The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
Article in Journal of Cellular and Molecular Medicine (January 2018)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
Article in Journal of Cellular and Molecular Medicine (January 2018)
Article in Nutrition and Cancer (April 2016)
Article in Clinical Nuclear Medicine (November 2015)